Dupixent vs Cosentyx
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Cosentyx | |
|---|---|---|
| Generic name | dupilumab | secukinumab |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | IL-17A Inhibitor (Biologic) |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Novartis |
| Year approved | 2017 | 2015 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $390M | $160M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions |
Frequently asked questions
Is Dupixent or Cosentyx better?
Neither is universally "better." Dupixent (dupilumab) and Cosentyx (secukinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Cosentyx?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.